Miyake Hiroaki, Murono Koji, Nagata Hiroshi, Nozawa Hiroaki, Kawai Kazushige, Hata Keisuke, Tanaka Toshiaki, Nishikawa Takeshi, Shuno Yasutaka, Sasaki Kazuhito, Ishihara Soichiro
Department of Surgical Oncology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Int J Colorectal Dis. 2019 May;34(5):801-809. doi: 10.1007/s00384-019-03259-5. Epub 2019 Feb 9.
The doubling times of tumor volume and tumor markers are associated with the prognosis of liver or lung metastases from colorectal cancer (CRC). However, no studies have assessed peritoneal metastases. Therefore, we aimed to elucidate the association between doubling time and the prognosis of patients who underwent radical surgery for metachronous peritoneal metastases of CRC.
We calculated the tumor doubling times (TDT) of peritoneal metastases and serum carcinoembryonic antigen-doubling times (CEA-DT) in 33 consecutive patients who underwent radical surgery for metachronous peritoneal metastases between January 2006 and April 2017. The impact of short TDT and CEA-DT on overall survival (OS) and relapse-free survival (RFS) was retrospectively reviewed.
In long TDT (> 137 days) group, the 5-year OS rate was 74.1% and median OS time was 6.6 years. In long CEA-DT (> 102 days) group, the 5-year OS rate was 50.0% and median OS time was 5.6 years. Conversely, in short TDT (≤ 137 days) and CEA-DT (≤ 102 days) group, the 5-year OS rates and median OS times were both 0.0% and 3.2 years, respectively. In the multivariate analysis, short TDT was an independent risk factor for poor RFS (P = 0.006) and OS (P = 0.010). Similarly, short CEA-DT was also a poor risk factor for RFS (P < 0.001) and OS (P = 0.012).
Short TDT and CEA-DT are independent risk factors for poor OS and RFS after surgery for metachronous peritoneal metastases of CRC. TDT and CEA-DT should be considered when selecting candidates for surgical resection.
肿瘤体积倍增时间和肿瘤标志物倍增时间与结直肠癌(CRC)肝转移或肺转移的预后相关。然而,尚无研究评估腹膜转移情况。因此,我们旨在阐明肿瘤体积倍增时间与接受根治性手术治疗的异时性CRC腹膜转移患者预后之间的关联。
我们计算了2006年1月至2017年4月期间连续33例接受根治性手术治疗异时性腹膜转移的患者的腹膜转移肿瘤倍增时间(TDT)和血清癌胚抗原倍增时间(CEA-DT)。回顾性分析了短TDT和CEA-DT对总生存期(OS)和无复发生存期(RFS)的影响。
在长TDT(>137天)组中,5年总生存率为74.1%,中位总生存时间为6.6年。在长CEA-DT(>102天)组中,5年总生存率为50.0%,中位总生存时间为5.6年。相反,在短TDT(≤137天)和CEA-DT(≤102天)组中,5年总生存率和中位总生存时间分别为0.0%和3.2年。多因素分析显示,短TDT是RFS(P = 0.006)和OS(P = 0.010)不良的独立危险因素。同样,短CEA-DT也是RFS(P < 0.001)和OS(P = 0.012)不良的危险因素。
短TDT和CEA-DT是异时性CRC腹膜转移手术后OS和RFS不良的独立危险因素。在选择手术切除候选患者时应考虑TDT和CEA-DT。